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Asian Society of Gynecologic Oncology (ASGO) 2nd Interna-
tional Workshop on Gynecologic Oncology was held in Kyoto 
Tokyu Hotel, on September 28th, 2012. A total of 213 medical 
doctors and students from 11 countries (Hong Kong, India, 
Indonesia, Japan, Korea, Malaysia, Philippines, Singapore, Tai-
wan, Thailand, and the USA) participated in the meeting. In 
this workshop, there were a total of 23 presentations in 7 ses-
sions including two sponsored seminars (Table 1).
The first session was an educational session which consisted 
of 3 lectures on the recent tends on gynecologic oncology. 
Dr. Konishi presented a multicenter study with ovarian cancer 
patients of which clinical information including transvaginal 
ultrasonography (TVS) finding of less than 12 months prior to 
the diagnosis of ovarian cancer was available. He concluded 
that approximately half of ovarian cancer develop secondarily 
from pre-existing, benign-appearing cysts or endometriotic 
cysts, whereas the remaining half, typically high-grade serous 
ovarian cancer, seem to develop suddenly from normal-ap-
pearing ovary. He also emphasized the limitation of screening 
programs using TVS. Dr. Aziz reviewed current understanding 
of neo-adjuvant chemotherapy (NAC) in advanced ovarian 
cancer and concluded that NAC prior to cytoreductive surgery 
was not superior to primary cytoreductive surgery, but effec-
tive in terms of less morbidity and shorter hospitalization. Dr. 
Devi gave a lecture on gestational trophoblastic disease (GTD) 
regarding diagnosis, prognostic scoring, and treatment for pri-
mary/ relapse/refractory disease, placental site trophoblastic 
tumor, and choriocarcinoma. Notably, she underscored that 
a few women died from the GTD, mainly because of late pre-
sentation and drug resistance. She concluded that novel ap-
proaches with improved efficacy and reduced toxicity needed 
to be identified and national registries of GTD in Asia should 
be established.
The second session comprised two symposia on the malig-
nancies with poor prognosis, cervical adenocarcinoma and 
uterine sarcomas. Three each of the lectures covered various 
aspects of the two cancers including pathology, imaging stud-
ies, and clinical management. Dr. Mikami presented his studies 
about cervical mucinous adenocarcinoma with gastric immu-
nophenotype. He proposed a concept of gastric-type adeno-
carcinoma (GAS) of the cervix for this tumor with a distinct 
morphology. He stated that GAS showed unfavorable clinical 
outcomes because of its aggressive behavior compared with 
usual-type of endocervical adenocarcinoma. In addition, he 
mentioned that absence of human papillomavirus (HPV) DNA 
in this particular type of tumor indicated that GAS arised via 
HPV-unrelated pathway. Thus, he concluded that special con-
siderations might be required for GAS in terms of carcinogen-
esis, prevention, early detection, and treatment strategy. Dr. 
Shiozawa presented a multicenter study for diagnostic criteria 
of minimal deviation adenocarcinoma (MDA) and lobular 
endocervical glandular hyperplasia (LEGH) of the cervix. He 
concluded that the combination of MRI, Pap smears, and gas-
tric mucin test will improve the accuracy of the preoperative 
diagnosis of MDA and LEGH. Next, Dr. Young-Tak Kim pointed 
out current problems in diagnosis and treatment of cervical 
adenocarcinoma by comprehensive review of his studies. He 
showed that adenocarcinoma differed from squamous cell 
carcinoma in terms of epidemiology, etiology and prognosis. 
Cervical adenocarcinoma is an independent prognostic indi-
cator of poor survival in patients with early stage cervical can-
cer with risk factors, regardless of the type of adjuvant radio-
therapy after radical hysterectomy. He concluded that novel 
treatment strategies specifically tailored to early stage cervical 
adenocarcinoma were needed.
In uterine sarcoma symposium, Dr. Silverberg gave us a 
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Table 1. Program of ASGO 2nd International Workshop on Gynecologic Oncology
Schedule Speaker
Opening remarks Toshiharu Kamura (President of ASGO, Japan)
Soon-Beom Kang (Past President of ASGO, Korea)
Shingo Fujii (President of IGCS, Japan)
Topic 1: Recent trends in gynecologic oncology Chair: Seung-Cheol Kim (Korea), Noriyuki Inaba (Japan)
      Toward understanding the natural history of ovarian cancer development:
        Is screening or early detection feasible?
Ikuo Konishi (Japan)
      Neoadjuvant chemotherapy of ovarian cancer Mohamad F. Aziz (Indonesia)
      Current management of gestational trophoblastic disease K. Uma Devi (India)
Topic 2: Round table discussion for malignancy with poor prognosis
(1) Cervical adenocarcinoma Chair: Hextan YS Ngan (Hong Kong), Tadashi Kimura (Japan)
      Cervical adenocarcinoma of gastric-type: a new entity Yoshiki Mikami (Japan)
      Minimal deviation adenocarcinoma (MDA) and lobular endocervical 
        hyperplasia (LEGH): differential diagnosis
Tanri Shiozawa (Japan)
      Current management of cervical adenocarcinoma Young-Tak Kim (Korea)
(2) Uterine sarcomas Chair: Kung-Liahng Wang (Taiwan), Hiroshi Kobayashi (Japan)
      Current topics on pathology in uterine sarcomas Steven G. Silverberg (USA)
      Does preoperative magnetic resonance imaging beneficial in uterine sarcoma? Ting-Chang Chang (Taiwan)
      Recent advances in management of uterine sarcomas Tadao Takano (Japan)
Luncheon seminar: Prevention of cervical cancer in Asia Chair: Kazunori Ochiai (Japan), Jo Kitawaki (Japan)
      HPV vaccination in Asia: globalization of combat against cervical cancer Sarikapan Wilailak (Thailand)
      How to get national immunization program for human papillomavirus 
        vaccination: sharing experience. The Japanese Expert Board for the 
        Eradication of Cervical Cancer
Ryo Konno (Japan)
Topic 3: Translational research for ovarian cancer Chair: Hee Sug Ryu (Korea), Hidetaka Katabuchi (Japan)
      Histotype-specific genomic alterations in ovarian cancer Liang Kee Goh (Singapore)
      The prognostic and therapeutic potential of AMP-activated protein 
        kinase in ovarian cancer
David W Chan (Hong Kong)
      Immunotherapy for recurrent ovarian cancer, a new challenge of strategy Junzo Hamanishi (Japan)
      Biology of ovarian clear cell carcinoma: microarray analysis and 
        bioinformatics
Noriomi Matsumura (Japan)
Topic 4: Updating gynecologic cancer surgery (Film session) Chair: Yin Nin Chia (Singapore), Hideharu Kanzaki (Japan) 
      Abdominal radical trachelectomy Tadayoshi Nagano (Japan)
      What kinds of approaches are needed to obtain optimal residual tumor 
        in the surgical management of advanced ovarian cancer?
Sang-Yoon Park (Korea)
      Laparoscopic surgery for gynecological cancer Kung-Liahng Wang (Taiwan)
Topic 5: Minimally invasive surgery for gynecologic cancer (Film session) Chair: Duk-Soo Bae (Korea), Daisuke Aoki (Japan)
      Robotic assisted staging of high risk endometrial cancer John F. Boggess (USA)
      Robotic radical hysterectomy for cervical cancer Yoon-Soon Lee (Korea)
      Fertility-sparing robotic assisted radical trachelectomy in early-stage 
        cervical cancer
Young Tae Kim (Korea)
Evening seminar: Neoadjuvant chemotherapy for cervical cancer Chair: Toru Sugiyama (Japan), Jyunzo Kigawa (Japan)
      NAC followed by radical hysterectomy for cervical cancer: future perspective Nobuhiro Takeshima (Japan)
      Radical hysterectomy for locally advanced cancer: essential techniques Masaki Mandai (Japan)
Closing remarks Joo-Hyun Nam (President-Elect of ASGO)
Ikuo Konishi (Congress President of the 3rd ASGO Meeting)
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lecture about pathological diagnosis of leiomyosarcoma and 
endometrial stromal sarcoma. He pointed out the difficulties 
in their diagnosis. Dr. Chang presented how MRI can be used 
to diagnose uterine sarcomas. He showed the usefulness 
of diffusion-weighted MRI in differentiating between leio-
myomas and malignant uterine tumors. Dr. Takano reviewed 
recent advances in the chemotherapeutic treatment against 
uterine sarcomas. He showed doxorubicin, ifosfamide, and 
gemcitabine plus docetaxel are the active agents against 
leiomyosarcoma. He also showed ifosfamide plus cisplatin, 
ifosfamide plus paclitaxel, and carboplatin plus paclitaxel are 
the active agents against uterine carcinosarcoma. Further-
more, bevacizumab and pazopanib are promising molecular-
targeted agents against uterine sarcomas.
The third session was about translational research for ovarian 
cancer. Dr. Goh presented her research about histotype-spe-
cific copy number alterations in ovarian cancer. She reported 
several potential drivers, including ERBB2 in mucinous, BRAF 
in serous, and TPM3 in endometrioid histotypes. She con-
cluded that identification of histotype-specific copy number 
alterations can pave the way for histotype-specific targeted 
drug therapy. Dr. Chan presented his research about AMP-
activated protein kinase (AMPK) in ovarian cancer. Decreased 
AMPK activity was significantly correlated with the up-regu-
lation of ERK/FOXM1 signaling cascade and advanced stage. 
He concluded that targeting AMPK by either pharmaceutical 
or natural AMPK activators could be considered as an alterna-
tive therapeutic regimen in the treatment of ovarian cancer. 
Dr. Hamanishi showed his research about tumor immunology 
in ovarian cancer. He showed that a novel classification of 
ovarian cancers could be established through the hierarchical 
clustering analysis based on tumor-infiltrating immune cells 
and immunological suppressors. He concluded that this result 
might support the application of Taylor-Made therapy based 
on the immune status of the patients. Dr. Matsumura pre-
sented the results of expression microarray analysis for ovarian 
clear cell carcinoma. He concluded that sorafenib might be 
effective in the treatment of this disease.
The following two sessions dealt with surgical films with 
expert lectures on updated gynecological cancer surgery 
including minimally invasive surgery. Dr. Tadayoshi Nagano 
presented a video about abdominal radical trachelectomy. He 
showed this technique might be feasible for women with ear-
ly-stage cervical carcinoma who wanted to preserve their fer-
tility. Dr. Wang presented a video about laparoscopic surgery 
for gynecological malignancies. Dr. Park presented a video 
about cytoreductive surgery for advanced ovarian cancer. He 
argued that optimal cytoreduction could be achieved even in 
a case with extensive upper abdomen involvement. Dr. Bog-
gess presented a video about robotic surgery for endometrial 
cancer, which included simple hysterectomy and retroperi-
toneal lymphadenectomy. Dr. Lee presented a video about 
robotic radical hysterectomy for cervical cancer. Dr. Young Tae 
Kim presented a video about robotic assisted radical trach-
electomy in early-stage cervical cancer.
Between the sessions, two sponsored luncheon and eve-
ning seminars covered pertinent hot issues in the prevention 
and treatment of uterine cervical cancer, respectively. In the 
luncheon seminar, Dr. Wilailak from Thailand and Dr. Konno 
from Japan gave presentations on the recent movements of 
HPV vaccination in Asia. Dr. Wilailak presented current top-
ics about HPV vaccination in Asia. She insisted that support 
from the government is necessary to increase the HPV vac-
cination rates. Dr. Konno presented how Japan pursued the 
vaccination program. He also presented the current problems 
in vaccination program in Japan. In the evening seminar, Dr. 
Takeshima and Dr. Mandai presented state of the art in the 
management of locally advanced cervical cancer. Dr. Takeshi-
ma presented the recent clinical trial that he conducted to 
evaluate the effectiveness of NAC followed by radical hys-
terectomy plus postoperative chemotherapy without radio-
therapy for stage IB2-IIB cervical cancer. He concluded that 
this treatment strategy would offer the advantage of minimiz-
ing radiation-induced morbidity, reserving radiotherapy for 
the possible pelvic recurrence. Dr. Mandai presented current 
problems in treating stage ⅡB cervical cancer. He emphasized 
the utility of “super-radical” hysterectomy and showed a video 
of the surgery.
This workshop was successful with active discussions after 
every presentation. Unfortunately, Chinese doctors were not 
able to attend the workshop due to the political issue that 
Chinese and Japanese governments are facing. I hope that 
every member of the ASGO will intimately communicate with 
each other for promoting both academic and social achieve-
ments in the near future.
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Appendix. Affiliations of the speakers
∙ Mohamad Farid Aziz, Department of Obstetrics and Gynecology, University of Indonesia, Depok, Indonesia 
∙ John Fletcher Boggess, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA 
∙ David W Chan, Department of Obstetrics and Gynecology, The University of Hong Kong, Hong Kong SAR, P. R. China 
∙ Ting-Chang Chang, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Medical Center, Taiwan
∙ K. Uma Devi, Department of Gynaecologic Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India 
∙ Liang Kee Goh, Cancer & Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore 
∙ Junzo Hamanishi, Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan 
∙ Young Tae Kim, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea 
∙ Young-Tak Kim, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 
∙ Ikuo Konishi, Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan 
∙ Ryo Konno, Department of Obstetrics and Gynecology, Jichi Medical University Saitama Medical Center, Saitama, Japan 
∙ Yoon Soon Lee, Gynecologic Cancer Center, Kyungpook National University Medical Center, Daegu, Korea 
∙ Masaki Mandai, Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan 
∙ Noriomi Matsumura, Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan 
∙ Yoshiki Mikami, Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan 
∙ Tadayoshi Nagano, The Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Osaka, Japan 
∙ Sang-Yoon Park, National Cancer Center, Goyang, Korea 
∙ Tanri Shiozawa, Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan 
∙ Steven G. Silverberg, University of Maryland, Baltimore, MD, USA 
∙ Tadao Takano, Clinical Research, Innovation, and Education Center, Tohoku University Hospital, Sendai, Japan 
∙ Nobuhiro Takeshima, Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan 
∙ Kung-Liahng Wang, Mackay Memorial Hospital, Taipei, Taiwan 
∙ Sarikapan Wilailak, Department of Obstetrics and Gynecology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
